Risultati della ricerca - M. Andre

Toward Design Principles for Biomolecular Condensates for Metabolic Pathways di Alain A.M. André, Nikita Rehnberg, Ankush Garg, Magnus Kjærgaard

Testo

22 | PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TUMOR SPREAD (Dmax) IN ADVANCED HODGKIN LYMPHOMA: ANCILLARY STUDY OF THE AHL2011 TRIAL di S. Kanoun, A. S. Cottereau, C. Rossi, C. Rossoni, C. Thieblemont, A. Stamatoullas, J. Dupuis, M. Andre, B. Lesne, Y. Al Tabaa, H. Guesquières, O. Casasnovas

Testo

856 | MARSUN, A PHASE III, MULTICENTER, OPEN LABEL, RANDOMIZED STUDY INVESTIGATING MOSUNETUZUMAB‐LENALIDOMIDE VERSUS INVESTIGATOR CHOICES IN R/R MARGINAL ZONE LYMPHOMAS di S. Carras, G. Cartron, F. Morcshhauser, A. Conconni, C. Buske, S. Luminari, M. Dreyling, M. Gomes Da Silva, M. André, C. Row, E. Gehlkopf, C. Thieblemont

Testo

Protection of naringenin chalcone by a pathogenesis‐related 10 protein promotes flavonoid biosynthesis in Marchantia polymorpha di Yanfei Zhou, Cyril Hamiaux, Christelle M. Andre, Janine M. Cooney, Kathy E. Schwinn, John W. van Klink, John L. Bowman, Kevin M. Davies, Nick W. Albert

Testo

254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY di C. Thieblemont, C. Row, T. Lamy, R. Aucagne, M. Tani, M. Merli, M. Deodato, S. V. Usai, C. Minoia, C. Bommier, C. Fournier, F. Bijou, M. C. Pirosa, A. Anastasia, L. Devizzi, S. Luminari, L. Arcaini, S. Chevreux, R. Gressin, M. André, N. Ielmini, L. Bonomini, E. Zucca, M. Callanan, A. Conconi

Testo

130 | TISLELIZUMAB, AN ANTI‐PD‐1 ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: FINAL ANALYSIS FROM THE LYSA PHASE 2 TIRHOL STUDY BGB‐A317‐210 di H. Ghesquières, K. Bouabdallah, M. André, P. Quittet, C. Borel, A. Stamatoullas Bastard, M. Gilbertson, F. Le Bras, C. Thieblemont, B. Delapierre, M. Touati, P. Feugier, L. Renaud, N. Morineau, T. Gastinne, I. Chaillol, R. Ramchandren, H. Shah, D. Modi, H. Allewelt, P. Fustier, J. Xu, R. Delarue, F. Morschhauser, C. Rossi

Testo

126 | THE EARLY‐STAGE CLASSIC HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTICATION INDEX (E‐HIPI): AN INDIVIDUALIZED PREDICTION MODEL UTILIZING OBJECTIVE AND CONTINUOUS VARIABLES di A. M. Evens, A. Rodday, M. J. Maurer, J. N. Upshaw, N. Counsell, S. Rossetti, C. Chang, Z. Cui, Q. Xiang, R. Mwangi, R. Advani, M. Andre, A. Gallamini, A. E. Hay, D. C. Hodgson, R. T. Hoppe, M. Hutchings, P. Johnson, E. Mou, S. Opat, J. Raemaekers, K. J. Savage, S. K. Parsons, J. Radford

Testo

64 | NIVOLUMAB + GemOx AS SECOND‐LINE THERAPY FOR PERIPHERAL T CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF A SUB‐COHORT OF THE RANDOMIZED NIVEAU TRIAL di G. Held, B. Altmann, L. de Leval, M. Dreyling, A. Kerkhoff, T. Gastinne, M. André, F. Offner, T. Weber, S. Wirths, R. Casasnovas, G. Cartron, C. Bonnet, L. Thurner, S. Mayer, G. Illerhaus, T. Illmer, S. Vigouroux, F. Morschhauser, V. Safar, A. Dąbrowska‐Iwanicka, M. Gomes da Silva, P. Gaulard, T. J. Molina, A. Rosenwald, R. Greil, U. Jaeger, A. Avigdor, M. Löffler, M. Ziepert, C. Haioun, V. Poeschel, R. Houot

Testo

52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY di C. Thieblemont, M. Tani, M. Brociner, M. Merli, M. Deodato, A. M. Frustaci, S. Luminari, L. Devizzi, F. Bijou, C. Bommier, A. Anastasia, A. J. M. Ferreri, L. Arcaini, C. Boccomini, L. Orsucci, P. Feugier, P. Sesques, M. Gomes da Silva, T. Lamy, C. Minoia, M. André, I. Del Giudice, R. Gressin, V. Cacheux, T. Zenz, C. De Ramon Ortiz, E. Gyan, G. Damaj, S. Chevreux, O. Casasnovas, U. Novak, L. Ysebaert, L. Fornecker, G. Gini, M. C. Pirosa, F. Zaja, S. V. Usai, N. Ielmini, L. Bonomini, E. Zucca, A. Conconi

Testo